RESUMO
OBJECTIVE: To compare the clinical and economical effects of foscarnet and a - interferon in treating chronic hepatitis B.METHODS:90 cases were randomly divided into two groups.Group A,foscarnet in a dose of 2.4g,i. v. ,b.i .d . for 1 month . Group B, a - interferon in a dose of 3 million units, im, q . d . for 3 months . The clinical effects were observed and evaluated with pharmacoeconomic cost - effectiveness analysis .RESL LTS In improving symptoms and liver function, two therapeutic regimes presented similar effect.But lower expenses were costed in unit effect of decreasing ALT in group B.In clearance of virus index, group A showed better effects and costed lower expenses in unit effect of HBeAg negative conversion. CONCLUSION: Both foscarnet and a-interferon presented fairly good therapeutic effect for chronic hepatitis B.In improving liver functions, two preparations showed similar clinical effect but a - interferon presented better economical effect. In antiviral efficacy,foscarnet showed better clinical and economical effects.
RESUMO
Objective To construct the recombinant plasmid of human MMP 1 clone and study its antigenecity of MMP 1 fusion protein. Methods The total RNA was extracted from human liver and used as a template for reverse transcription. After PCR amplification, a 1 432 bp fragment was obtained and cloned into T vector. After digested with restriction enzyme, the target fragment was subcloned into plasmid pMAL c2x. The recombinant plasmid was transferred into JM109 which can express a fusion protein. We analyze the protein with SDS PAGE and Western blot. Results We obtained human MMP 1 gene and its recombinant plasmid clone. The expressed protein can be recognized by MMP 1 polyclonal antibody in Western blot.Conclusions We obtained the MMP 1 protein with antigenicity. The fusion protein can be used to prepare polyclonal antibody against MMP 1.